Lack of association between the FAS/FASL polymorphisms and cervical cancer risk: A meta-analysis

Abstract

Abstract. FAS/FASL gene promoter polymorphisms are associated with cervical cancer risk, however, results from previous studies have been conflicting. To obtain a more precise estimation of the association between these polymorphisms and cancer risk, a meta-analysis was performed. All eligible studies up to November 1st, 2012, concerning FAS-670 A/G, FAS-1377 G/A and FASL-844 T/C polymorphisms and cervical cancer risk, were collected from the following electronic databases: PubMed, Excerpta Medica Database and Chinese Biomedical Literature Database. The odds ratio (OR) and 95% confidence interval (95% CI) were used to assess the strength of the association via the additive, codominant, dominant and recessive models. In total, 10 publications with 11 case-control studies (10 on FAS-670 A/G, 5 on FAS-1377 G/A and 6 on FASL-844 T/C polymorphisms) were included in this meta-analysis. No association between FAS-670 A/G, FAS-1377 G/A and FASL-844 T/C polymorphisms and cervical cancer susceptibility for all the genetic models was identified. Following stratification of the studies by ethnicity or source of controls, similar results were obtained. In conclusion, our findings showed that the FAS-670 A/G, FAS-1377 G/A and FASL-844 T/C polymorphisms are not associated with cervical cancer risk. Future studies with larger sample sizes are required to further evaluate these associations.

Genetic Susceptibility for Cervical Cancer in African Populations: What Are the Host Genetic Drivers?

“…In addition, Zoodsma et al (2005) showed a relationship between FasR 670A ‡G and increased risk of adenocarcinoma and not squamous cell carcinoma of the cervix. However, in another study conducted in Chinese women, as well as in Caucasian populations, there was no association between Fas SNPs and cervical cancer susceptibility (Chen et al, 2013;Du et al, 2013;Engelmark et al, 2004b;Pavlidou et al, 2016;Sun et al, 2005) resonating with the findings from African populations (Table 3).…”

“…The Fas receptor (FasR) also known as CD95 is a tumor necrosis factor that activates downstream apoptotic activity through interaction with Fas ligand (FasL) (Du et al, 2013). Viral infection mediates an immune transactivation of the caspase cascade, thus inducing activation induced cell death (Siegel, 2006;Ueda et al, 2006).…”

FAS rs2234767 and rs1800682 polymorphisms jointly contributed to risk of colorectal cancer by affecting SP1/STAT1 complex recruitment to chromatin

“…Although the FAS polymorphisms have been widely investigated their association with multiple tumors susceptibility 30 31 32 , the studies on mechanisms underlying the association were limited. The rs2234767 and rs1800682 polymorphisms can alter the SP1 and STAT1 binding site, leading to downregulated FAS expression 13 14 .…”